Selective haematological cancer eradication with preserved haematopoiesis.

ABSTRACT: Haematopoietic stem cell (HSC) transplantation (HSCT) is the only curative treatment for a broad range of haematological malignancies, but the standard of care relies on untargeted chemotherapies and limited possibilities to treat malignant cells after HSCT without affecting the transplanted healthy cells¹. Antigen-specific cell-depleting therapies hold the promise of much more targeted elimination of diseased cells, as witnessed in the past decade by the revolution of clinical practice for B cell malignancies². However, target selection is complex and limited to antigens expressed on subsets of haematopoietic cells, resulting in a fragmented therapy landscape with high development costs^2-5. Here we demonstrate that an antibody-drug conjugate (ADC) targetin

SUBMITTER: Garaude S 

PROVIDER: S-EPMC11186773 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature